

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side		result set	
	<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<u>L5</u>	(gp39 or cd40L or cd40 adj ligand or cd154 or 5c8) and (treat\$ or therap\$ or inhibit\$ or suppress\$ or prevent\$ or administ\$)same (atherosclerosis)	278	<u>L5</u>
<u>L4</u>	(gp39 or cd40L or cd40 adj ligand or cd154 or 5c8) same (atherosclerosis)	41	<u>L4</u>
<u>L3</u>	(gp39 or cd40L or cd40 adj ligand or cd154 or 5c8) and (atherosclerosis)	274	<u>L3</u>
<u>L2</u>	yellin-michael\$	12	<u>L2</u>
<u>L1</u>	yellin-michael	0	<u>L1</u>

END OF SEARCH HISTORY

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#) [Search Form](#) [Posting Counts](#) [Show S Numbers](#) [Edit S Numbers](#) [Preferences](#) [Cases](#)**Search Results -**

Term	Documents
GP39.DWPI,EPAB,JPAB,USPT,PGPB.	215
GP39S	0
CD40L.DWPI,EPAB,JPAB,USPT,PGPB.	602
CD40LS.DWPI,EPAB,JPAB,USPT,PGPB.	2
CD40.DWPI,EPAB,JPAB,USPT,PGPB.	1780
CD40S	0
LIGAND.DWPI,EPAB,JPAB,USPT,PGPB.	71876
LIGANDS.DWPI,EPAB,JPAB,USPT,PGPB.	49822
CD154.DWPI,EPAB,JPAB,USPT,PGPB.	228
CD154S.DWPI,EPAB,JPAB,USPT,PGPB.	1
5C8.DWPI,EPAB,JPAB,USPT,PGPB.	95
((GP39 OR CD40L OR CD40 ADJ LIGAND OR CD154 OR 5C8) SAME (ATHEROSCLEROSIS)).USPT,PGPB,JPAB,EPAB,DWPI.	41

[There are more results than shown above. Click here to view the entire set.](#)

**Database:**

US Patents Full-Text Database  
US Pre-Grant Publication Full-Text Database  
JPO Abstracts Database  
EPO Abstracts Database  
Derwent World Patents Index

**Search:**

**Search History**DATE: **Monday, January 13, 2003** [Printable Copy](#) [Create Case](#)

Set Name Query  
side by side

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ

<u>L4</u>	(gp39 or cd40L or cd40 adj ligand or cd154 or 5c8) same (atherosclerosis)	41	<u>L4</u>
<u>L3</u>	(gp39 or cd40L or cd40 adj ligand or cd154 or 5c8) and (atherosclerosis)	274	<u>L3</u>
<u>L2</u>	yellin-michael\$	12	<u>L2</u>
<u>L1</u>	yellin-michael	0	<u>L1</u>

END OF SEARCH HISTORY

Hit Count Set Name  
result set

## WEST

 Generate Collection 

L4: Entry 21 of 41

File: USPT

Jan 22, 2002

DOCUMENT-IDENTIFIER: US 6340459 B1

TITLE: Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients

Detailed Description Text (49):

In embodiments of this invention the condition dependent on CD40 ligand-induced activation of endothelial cells is selected from the group consisting of atherosclerosis, reperfusion injury, allograft rejection, organ rejection, and chronic inflammatory autoimmune diseases.

Detailed Description Text (50):

In a specific embodiment the atherosclerosis is accelerated atherosclerosis associated with organ transplantation. In situ CD40 and CD40L expression in accelerated atherosclerosis associated with transplant rejection have been studied. Frozen sections of coronary arteries from 4 heart transplant patients that required retransplantation due to accelerated atherosclerosis were analyzed by routine immunohistochemistry utilizing anti-CD40 mAb G28.5, anti-CD40L mAb 5C8 or control mAbs. Routine H & E staining revealed the typical intimal hyperplasia, smooth muscle cell proliferation, and inflammatory cell infiltration associated with the disease. CD40 was widely expressed in the lesions: endothelial cells, foam cells and infiltrating inflammatory cells all express CD40. CD40L immunoreactivity was observed as discrete, faint staining of infiltrating mononuclear cells, presumably CD4+ T cells. Together, these studies demonstrate the presence of CD40L+ mononuclear cells and CD40+ endothelial cells, foam cells, and inflammatory cells in situ in lesions of accelerated atherosclerosis associated with transplantation.

Detailed Description Text (54):

This invention provides a method of treating a condition dependent on CD40 ligand-induced activation of macrophages in a subject, comprising the above-described method of inhibiting activation of macrophages by CD40 ligand in a subject. In specific embodiments, the condition dependent on CD40 ligand-induced activation of macrophages is atherosclerosis or rheumatoid arthritis.

Detailed Description Text (135):

Finally, endothelial cells are activated in a variety of diseases mediated by CD4.sup.+ T cells. For example, endothelial cell surface adhesion molecules are upregulated in rheumatoid arthritis (62), scleroderma (63) and in transplant rejection (64). In addition, CD4.sup.+ T cells play roles in atherosclerosis (65) and accelerated atherosclerosis associated with transplantation (60). The precise mechanistic role of CD40L mediated interactions with endothelial cells in these diseases is not known. However, an antibody to CD40L, MR1, inhibits murine models of diseases mediated by CD4.sup.+ T cells and/or inflammatory cell infiltrates. For example, MR1 prevents the synovial lining cell hypertrophy and cellular infiltrate associated with collagen-induce arthritis, a murine model of rheumatoid arthritis (66). Moreover, MR1 inhibits a murine model of multiple sclerosis (EAE) and inhibits allograft rejection (67). Blocking CD40L dependent interactions with endothelial cells and/or fibroblasts mediates, in part, these effects of MR1. The results disclosed herein suggest that CD40L-CD40 interactions on the surface of endothelial cells play immunopathogenic roles in inflammatory diseases.

## WEST

[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#) [Search Form](#) [Posting Counts](#) [Show S Numbers](#) [Edit S Numbers](#) [Preferences](#) [Cases](#)

## Search Results -

Term	Documents
GP39.DWPI,EPAB,JPAB,USPT,PGPB.	215
GP39S	0
CD40L.DWPI,EPAB,JPAB,USPT,PGPB.	602
CD40LS.DWPI,EPAB,JPAB,USPT,PGPB.	2
CD40.DWPI,EPAB,JPAB,USPT,PGPB.	1780
CD40S	0
LIGAND.DWPI,EPAB,JPAB,USPT,PGPB.	71876
LIGANDS.DWPI,EPAB,JPAB,USPT,PGPB.	49822
CD154.DWPI,EPAB,JPAB,USPT,PGPB.	228
CD154S.DWPI,EPAB,JPAB,USPT,PGPB.	1
5C8.DWPI,EPAB,JPAB,USPT,PGPB.	95
((GP39 OR CD40L OR CD40 ADJ LIGAND OR CD154 OR 5C8) AND (TREAT\$ OR THERAP\$ OR INHIBIT\$ OR SUPPRESS\$ OR PREVENT\$ OR ADMINIST\$)SAME (ATHEROSCLEROSIS)).USPT,PGPB,JPAB,EPAB,DWPI.	278

[There are more results than shown above. Click here to view the entire set.](#)

US Patents Full-Text Database  
 US Pre-Grant Publication Full-Text Database  
 JPO Abstracts Database  
 EPO Abstracts Database  
 Derwent World Patents Index

Database: IBM Technical Disclosure Bulletins

Search:

L5

[Refine Search](#)[Recall Text](#)[Clear](#)

## Search History

DATE: Monday, January 13, 2003 [Printable Copy](#) [Create Case](#)

Set Name Query  
side by sideHit Count Set Name  
result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ

<u>L5</u>	(gp39 or cd40L or cd40 adj ligand or cd154 or 5c8) and (treat\$ or therap\$ or inhibit\$ or suppress\$ or prevent\$ or administ\$)same (atherosclerosis)	278	<u>L5</u>
<u>L4</u>	(gp39 or cd40L or cd40 adj ligand or cd154 or 5c8) same (atherosclerosis)	41	<u>L4</u>
<u>L3</u>	(gp39 or cd40L or cd40 adj ligand or cd154 or 5c8) and (atherosclerosis)	274	<u>L3</u>
<u>L2</u>	yellin-michael\$	12	<u>L2</u>
<u>L1</u>	yellin-michael	0	<u>L1</u>

END OF SEARCH HISTORY

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#) [Search Form](#) [Posting Counts](#) [Show S Numbers](#) [Edit S Numbers](#) [Preferences](#) [Cases](#)**Search Results -**

Term	Documents
GP39.DWPI,EPAB,JPAB,USPT,PGPB.	215
GP39S	0
CD40L.DWPI,EPAB,JPAB,USPT,PGPB.	602
CD40LS.DWPI,EPAB,JPAB,USPT,PGPB.	2
CD40.DWPI,EPAB,JPAB,USPT,PGPB.	1780
CD40S	0
LIGAND.DWPI,EPAB,JPAB,USPT,PGPB.	71876
LIGANDS.DWPI,EPAB,JPAB,USPT,PGPB.	49822
CD154.DWPI,EPAB,JPAB,USPT,PGPB.	228
CD154S.DWPI,EPAB,JPAB,USPT,PGPB.	1
5C8.DWPI,EPAB,JPAB,USPT,PGPB.	95
((GP39 OR CD40L OR CD40 ADJ LIGAND OR CD154 OR 5C8) AND (TREAT\$ OR THERAP\$ OR INHIBIT\$ OR SUPPRESS\$ OR PREVENT\$ OR ADMINIST\$)SAME (ATHEROSCLEROSIS)).USPT,PGPB,JPAB,EPAB,DWPI.	278

[There are more results than shown above. Click here to view the entire set.](#)

Database:

Search:

**Search History****DATE: Monday, January 13, 2003** [Printable Copy](#) [Create Case](#)